Penumbra, Inc. (NYSE:PEN – Get Free Report) has earned a consensus recommendation of “Hold” from the seventeen research firms that are presently covering the stock, Marketbeat reports. Fourteen investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $361.3333.
A number of brokerages have recently commented on PEN. UBS Group reaffirmed a “neutral” rating and set a $374.00 price objective on shares of Penumbra in a research note on Thursday, February 26th. Evercore reaffirmed an “outperform” rating and set a $335.00 price objective on shares of Penumbra in a research note on Thursday, May 7th. Citigroup dropped their price objective on shares of Penumbra from $374.00 to $350.00 and set a “neutral” rating on the stock in a research note on Thursday, May 7th. Finally, Wall Street Zen raised shares of Penumbra to a “hold” rating in a research note on Saturday, May 9th.
View Our Latest Research Report on PEN
Insider Activity
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Hsbc Holdings PLC lifted its position in shares of Penumbra by 2.3% during the 4th quarter. Hsbc Holdings PLC now owns 1,527 shares of the company’s stock valued at $475,000 after buying an additional 35 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of Penumbra by 27.1% during the 4th quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock valued at $55,000 after buying an additional 38 shares in the last quarter. Swiss Life Asset Management Ltd lifted its position in shares of Penumbra by 2.3% during the 4th quarter. Swiss Life Asset Management Ltd now owns 1,728 shares of the company’s stock valued at $537,000 after buying an additional 39 shares in the last quarter. Abbot Financial Management Inc. lifted its position in shares of Penumbra by 1.3% during the 3rd quarter. Abbot Financial Management Inc. now owns 3,254 shares of the company’s stock valued at $824,000 after buying an additional 42 shares in the last quarter. Finally, Glenview Trust Co lifted its position in shares of Penumbra by 5.0% during the 3rd quarter. Glenview Trust Co now owns 904 shares of the company’s stock valued at $229,000 after buying an additional 43 shares in the last quarter. Hedge funds and other institutional investors own 88.88% of the company’s stock.
Penumbra Price Performance
Shares of NYSE PEN opened at $319.53 on Friday. The stock has a market capitalization of $12.57 billion, a price-to-earnings ratio of 73.62, a PEG ratio of 1.97 and a beta of 0.71. Penumbra has a 12 month low of $221.26 and a 12 month high of $362.41. The firm’s 50 day simple moving average is $326.08 and its 200-day simple moving average is $327.19. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.02 and a quick ratio of 3.95.
Penumbra (NYSE:PEN – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.82 EPS for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.24). The firm had revenue of $374.76 million for the quarter, compared to analyst estimates of $370.47 million. Penumbra had a return on equity of 10.87% and a net margin of 11.76%.Penumbra’s revenue for the quarter was up 15.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.83 EPS. Analysts expect that Penumbra will post 5.08 EPS for the current year.
Penumbra Company Profile
Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.
At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.
Featured Stories
- Five stocks we like better than Penumbra
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.
